Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Stage IIIB Hepatocellular Carcinoma AJCC V8: early-phase trial registry

4 of 7 indexed Stage IIIB Hepatocellular Carcinoma AJCC V8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Stage IIIB Hepatocellular Carcinoma AJCC V8: 7 US clinical trials tracked, 4 recruiting.

Stage IIIB Hepatocellular Carcinoma AJCC V8 is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition stage-iiib-hepatocellular-carcinoma-ajcc-v8

OPEN 4 | RECR 57% | LATE 0 | EARLY 6 | RANK #2497 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Stage IIIB Hepatocellula (th…57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Stage IIIB Hepatocellular Carcinoma AJCC V8

Stage IIIB Hepatocellular Carcinoma AJCC V8 lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage IIIB Hepatocellular Carcinoma AJCC V8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage IIIB Hepatocellular Carcinoma AJCC V8 is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage IIIB Hepatocellular Carcinoma AJCC V8 research.

    M.D. Anderson Cancer Center accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage IIIB Hepatocellular Carcinoma AJCC V8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 25 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Stage IIIB Hepatocellular Carcinoma AJCC V8 research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Top Sponsors

M.D. Anderson Cancer Center 2 trials
Mary Feng, MD 1 trials
Academic and Community Cancer Research United 1 trials
Emory University 1 trials
City of Hope Medical Center 1 trials
National Cancer Institute (NCI) 1 trials

Named interventions

Most-linked intervention names on Stage IIIB Hepatocellular Carcinoma AJCC V8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tremelimumab Biological
2 trials
Lenvatinib Drug
2 trials
Durvalumab Biological
2 trials
Yttrium-90 Microsphere Radioembolization Procedure
1 trials
Yttrium Y 90 Glass Microspheres Radiation
1 trials
Hepatobiliary Iminodiacetic Acid Scan Other
1 trials
Pevonedistat Drug
1 trials
Recombinant Interferon Alpha 2b-like Protein Biological
1 trials

US sites by state

Facility locations filed on Stage IIIB Hepatocellular Carcinoma AJCC V8 trials. A trial with sites in several states counts in each.

California 3 trials
Arizona 3 trials
Texas 2 trials
Wisconsin 1 trials
South Dakota 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stage IIIB Hepatocellular Carcinoma AJCC V8 page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Stage IIIB Hepatocellular Carcinoma AJCC V8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • M.D. Anderson Cancer Center sponsors the most Stage IIIB Hepatocellular Carcinoma AJCC V8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIB Hepatocellular Carcinoma AJCC V8 condition card totals 7 registered trials; most-linked intervention Tremelimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.